A PHASE IIB STUDY TO INVESTIGATE THE TREATMENT-SPARING EFFECTS OF AEROVANT™ (AER 001 INHALATION POWDER) IN ASTHMA PATIENTS NOT FULLY CONTROLLED ON CURRENT THERAPY
(Aerovance)
Description
This study is testing a new drug which is an anti IL-4 and IL-13. Some cells located inside lungs and along the airways are known T-helper cells. When activated they make lots of different chemicals including IL-4 and IL-13. IL-4 and IL-13 are needed to start the inflammation process. This new drug should block IL-4 and IL-13 and slow down or stop the inflammation process.
Major Requirements
· Non smoking asthmatic
· Using an inhaled combination product for more than 4 weeks
********************************************************************************
BRONCHOSCOPIC EXPLORATORY RESEARCH STUDY OF BIOMARKERS IN CORTICOSTERIOD-REFRACTORY ASTHMA
(BOBCAT)
Description
The goal of this study is to create new tests that will tell doctors what is happening inside the lungs, so that these tests can be used to better choose the best type of asthma treatment for subjects.
Major Requirements
· Non smoking asthmatic
· Be willing to have a bronchoscopy
A medical procedure to put a small tube in you airways. Once the tube is placed in your airways, samples will be collected.
· Having uncontrolled asthma symptoms even while using a high dose inhaled corticosteroids
· Cannot be using Xolair
*********************************************************************************
AN EFFICACY AND SAFETY STUDY OF RESLIZUMAB (CTX55700) IN THE TREATMENT OF POORLY CONTROLLED ASTHMA IN SUBJECTS WITH EOSINOPHILIC AIRWAY INFLAMMATION
(Ception)
Description
This study is testing a new drug which is an anti IL-5. Some cells located inside lungs and along the airways are known as eosinophils. In a large number of asthmatic lungs, eosinophils and other chemicals can be identified, whereas these are absent from healthy lungs. Suppressing eosinophils is usually associated with improving asthma symptoms. The study drug is an anti IL-5 drug, stopping IL-5 decreases the inflammatory process
Major Requirements
· Non smoking asthmatic
· Using an inhaled combination product for more than 4 weeks
· Have a blood draw to determine your eosinophil count
********************************************************************************
GSK RES100767 A Study to Validate Key Therapeutic Targets and Characterise Their Response to Corticosteroids in Multiple Asthma Phenotypes
Description
This study is looking at how five different groups react to a 2 week course of a corticosteroid. The five groups are mild asthmatics, moderate asthmatics, severe asthmatics, asthmatic smokers and normal (non asthmatic subjects). The sponsor is trying to find different genes between the groups and how these specific genes react to steroids.
Major Requirements
· Have asthma
· Be willing to have a bronchoscopy
A medical procedure to put a small tube in you airways. Once the tube is placed in your airways, samples will be collected.
*********************************************************************************
Best Adjustment Strategy for Asthma in the Long Term (BASALT)
Description
Current management strategies for asthma are based on consensus guidelines and clinical judgment. Accordingly, it is common for asthma therapy to require periodic adjustments in the intensity of therapy, increasing it when signs or symptoms of the disease worsen and decreasing it when they improve . However, guidelines for making these adjustments, especially downward adjustments in the intensity of treatment, have not been well established. This study is looking at creating guidelines for asthmatics self-adjusting their medication.
Major Requirements
· Non smoking asthmatic
· Need for a daily controller medication (examples included Advair, Flovent, Symbicort ect)
*********************************************************************************
Genotype-Phenotype Interaction in severe asthma
Description
The purpose of this project is to study subjects with severe asthma to try and understand why and how severe disease develops. This is an observational study only; there are no therapeutic interventions being studied. This study will explore the relationships between clinical symptoms/signs of asthma severity, candidate genes that may influence disease severity and inflammatory substances and cells (in the lungs) that may lead to irreversible changes in the lungs and hence, severe asthma.
Major Requirements
· Be a non-smoking asthmatic
*********************************************************************************
FOR PEOPLE WITH COPD (chronic obstructive pulmonary disease)
This is defined as having emphysema or a disease called chronic bronchitis
A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 µg once daily with open label tiotropium 18 µg once daily versus open label tiotropium 18 µg once daily in patients with moderate-to-severe chronic obstructive pulmonary disease
Description
This study is using a new drug that has long acting effects while also comparing it to a medication that is currently on the market. The approved medication is used twice a day (examples formoterol and salmeterol). These types of medications are used to enhance long term control of COPD symptoms. The new medication is used once a day.
Major Requirements
· Have COPD (chronic obstructive pulmonary disease)
· Over 40 years of age
· CANNOT have asthma or a history of asthma
*********************************************************************************